Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nexlizet in Acute Coronary Syndrome (CLEAR ACS)
NCT05263778Phase 4Unknown
- Sponsor
- Kaiser Permanente
- Start
- Mar 2022
- Primary completion
- Jun 2023
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in hypercholesterolemia comparing Nexlizet Arm with Placebo Arm (2 arms). Primary endpoint: Low-Density Lipoprotein Cholesterol at 12 weeks. Status: unknown.
02
Drugs
bempedoic acid + ezetimibe
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT05263778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05263778.